Compare KGS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | PTCT |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.5B |
| IPO Year | 2023 | 2006 |
| Metric | KGS | PTCT |
|---|---|---|
| Price | $64.92 | $78.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $57.17 | ★ $80.65 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 58.93 | ★ 264.48 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,308,100,000.00 | $264,734,000.00 |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $7.96 | $17.70 |
| P/E Ratio | $330.00 | ★ N/A |
| Revenue Growth | 12.83 | ★ 36.19 |
| 52 Week Low | $30.06 | $43.18 |
| 52 Week High | $77.68 | $90.87 |
| Indicator | KGS | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 46.13 |
| Support Level | $55.10 | $73.41 |
| Resistance Level | $77.13 | $79.67 |
| Average True Range (ATR) | 2.99 | 3.51 |
| MACD | -0.58 | -1.26 |
| Stochastic Oscillator | 11.50 | 13.27 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.